Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl.

[1]  S. Sherratt,et al.  Abstract 16934: Eicosapentaenoic Acid Inhibits Lipoprotein(a) With Higher Rates of Oxidation Compared to Non-Modified Low-Density Lipoprotein in vitro , 2023, Circulation.

[2]  Deepak L. Bhatt,et al.  Relating Lipoprotein(a) Concentrations to Cardiovascular Event Risk After Acute Coronary Syndrome: A Comparison of 3 Tests , 2023, Circulation.

[3]  Y. V. D. van der Burgt,et al.  Developing an SI-traceable Lp(a) reference measurement system: a pilgrimage to selective and accurate apo(a) quantification , 2023, Critical reviews in clinical laboratory sciences.

[4]  R. Rosenson,et al.  Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2/3. , 2023, Journal of the American College of Cardiology.

[5]  P. Libby,et al.  Comparative Effects of Mineral Oil, Corn Oil, Eicosapentaenoic Acid, and Docosahexaenoic Acid in an In Vitro Atherosclerosis Model , 2023, Journal of the American Heart Association.

[6]  Hong Wang,et al.  Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease. , 2022, The New England journal of medicine.

[7]  F. Kronenberg,et al.  Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement , 2022, European heart journal.

[8]  Hong Wang,et al.  Study Design and Rationale for the OCEAN(a)-DOSE (Olpasiran trials of Cardiovascular Events And LipoproteiN(a) reduction-DOSE Finding Study) Trial. , 2022, American heart journal.

[9]  F. Kronenberg.  Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill? , 2022, Atherosclerosis.

[10]  A. Scrimgeour,et al.  Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels. , 2022, JAMA.

[11]  Deepak L. Bhatt,et al.  SAFETY OF SAME DAY DISCHARGE AFTER TRANSVENOUS LEAD EXTRACTION , 2022, Journal of the American College of Cardiology.

[12]  M. Koschinsky,et al.  Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association. , 2021, Arteriosclerosis, thrombosis, and vascular biology.

[13]  Deepak L. Bhatt,et al.  Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial , 2020, European heart journal.

[14]  Deepak L. Bhatt,et al.  Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies , 2020, European heart journal supplements : journal of the European Society of Cardiology.

[15]  R. Mason,et al.  Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro. , 2020, Biochimica et biophysica acta. Biomembranes.

[16]  Deepak L. Bhatt,et al.  Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. , 2020, Journal of the American College of Cardiology.

[17]  J. Tardif,et al.  Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. , 2020, The New England journal of medicine.

[18]  Deepak L. Bhatt,et al.  Reduction in First and Total Ischemic Events With Icosapent Ethyl Across Baseline Triglyceride Tertiles. , 2019, Journal of the American College of Cardiology.

[19]  Deepak L. Bhatt,et al.  Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT. , 2019, Journal of the American College of Cardiology.

[20]  F. Kronenberg,et al.  Estimation of the Required Lipoprotein(a)-Lowering Therapeutic Effect Size for Reduction in Coronary Heart Disease Outcomes: A Mendelian Randomization Analysis. , 2019, JAMA cardiology.

[21]  A. Keech,et al.  Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk: Insights From the FOURIER Trial , 2019, Circulation.

[22]  Deepak L. Bhatt,et al.  Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia , 2019, The New England journal of medicine.

[23]  J Wouter Jukema,et al.  Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome , 2018, The New England journal of medicine.

[24]  F. Kronenberg,et al.  Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials , 2018, The Lancet.

[25]  James R. Staley,et al.  Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis , 2018, JAMA cardiology.

[26]  A. Keech,et al.  Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease , 2017, The New England journal of medicine.

[27]  Deepak L. Bhatt,et al.  Rationale and design of REDUCE‐IT: Reduction of Cardiovascular Events with Icosapent Ethyl–Intervention Trial , 2017, Clinical cardiology.

[28]  S. Tsimikas.  A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. , 2017, Journal of the American College of Cardiology.

[29]  B. Nordestgaard,et al.  Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology , 2016, Journal of Lipid Research.

[30]  A. Khera,et al.  Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention An Intervention Trial Evaluating Rosuvastatin) , 2013, Circulation.

[31]  Nancy R Cook,et al.  Advances in Measuring the Effect of Individual Predictors of Cardiovascular Risk: The Role of Reclassification Measures , 2009, Annals of Internal Medicine.

[32]  M. Pencina,et al.  Evaluating the added predictive ability of a new marker: From area under the ROC curve to reclassification and beyond , 2008, Statistics in medicine.